COLEC10

Chr 8AR

collectin subfamily member 10

Also known as: 3MC3, CL-10, CL-34, CLL1

This gene encodes a member of the C-lectin family, proteins that possess collagen-like sequences and carbohydrate recognition domains. The other members of this family are secreted proteins and bind to carbohydrate antigens on microorganisms facilitating their recognition and removal. This gene product is a cytosolic protein, a characteristic that suggests that it may have different biological functions than other C-lectins. [provided by RefSeq, Jul 2008]

OMIMResearchGenerating clinical summary…
LOFmechanismARLOEUF 0.961 OMIM phenotype
Clinical SummaryCOLEC10
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
7 unique Pathogenic / Likely Pathogenic· 44 VUS of 64 total submissions
💊
Clinical Trials
9 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.96LOEUF
pLI 0.003
Z-score 1.66
OE 0.49 (0.270.96)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
0.03Z-score
OE missense 0.99 (0.871.13)
158 obs / 159.0 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.49 (0.270.96)
00.351.4
Missense OE?0.99 (0.871.13)
00.61.4
Synonymous OE?0.88
01.21.6
LoF obs/exp: 6 / 12.3Missense obs/exp: 158 / 159.0Syn Z: 0.71
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongCOLEC10-related 3MC syndromeLOFAR

This gene — mechanism propensity

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.7033th %ile
GOF
0.6442th %ile
LOF
0.3067th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

64 submitted variants in ClinVar

Classification Summary

Pathogenic5
Likely Pathogenic2
VUS44
Likely Benign8
Benign3
5
Pathogenic
2
Likely Pathogenic
44
VUS
8
Likely Benign
3
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
3
1
1
0
5
Likely Pathogenic
1
1
0
0
2
VUS
0
43
1
0
44
Likely Benign
0
4
0
4
8
Benign
0
0
1
2
3
Total4493662

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

55 pathogenic / likely-pathogenic (of 63) ClinVar copy-number / structural variants overlap COLEC10 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

COLEC10 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

AML (Acute Myeloid Leukemia)CAR-T

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

NOT YET RECRUITING
NCT07338357Phase EARLY_PHASE1First Affiliated Hospital of Guangxi Medical UniversityStarted 2026-01-05
CAR-T
LeukemiaAcute Myeloid Leukemia

BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

NOT YET RECRUITING
NCT06347458Phase PHASE1Guangzhou Bio-gene Technology Co., LtdStarted 2024-04
BG1805
Acute Myeloid Leukemia

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

RECRUITING
NCT03222674Phase PHASE1, PHASE2Shenzhen Geno-Immune Medical InstituteStarted 2025-07-15
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Leukemia, Myeloid, Acute

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

RECRUITING
NCT06118788Phase PHASE1, PHASE2Guangzhou Bio-gene Technology Co., LtdStarted 2024-03-07
BG1805
Acute Myeloid Leukemia

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

RECRUITING
NCT06880354Phase PHASE1Institute of Hematology & Blood Diseases Hospital, ChinaStarted 2025-05-22
CLL1 and CD38 Dual-Target CAR-T Cell Injection
Acute Myeloid Leukemia

Multiple CAR-T Cell Therapy Targeting AML

RECRUITING
NCT04010877Phase PHASE1, PHASE2Shenzhen Geno-Immune Medical InstituteStarted 2025-08-01
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
Acute Myeloid Leukemia (AML)

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

RECRUITING
NCT07668557Phase PHASE1iCell Gene TherapeuticsStarted 2026-06-10
Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide
Acute Myeloid LeukemiaChimeric Antigen Receptor T-cellUniversal CLL1 CAR-T

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

NOT YET RECRUITING
NCT07432100Phase PHASE1Mingfeng ZhaoStarted 2026-02
universal CLL1 CAR-T cells
Acute Myeloid Leukemia

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

ACTIVE NOT RECRUITING
NCT04219163Phase PHASE1Baylor College of MedicineStarted 2020-07-09
CLL-1.CAR T cells